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Background and Purpose Thromboembolic stroke is likely to occur in patients with a restricted cerebral blood flow reserve. Our aims were to determine (1) whether symptomatic patients had any significant hemodynamic restriction ipsilateral to carotid occlusive disease compared with patients whose carotid stenosis is asymptomatic and (2) whether patients with carotid occlusive disease have impaired cerebral perfusion reserve compared with control subjects.
Methods We compared cerebral blood flow and collateral capacity using the 133 Xe inhalation method and acetazolamide test in symptomatic (n=10) and asymptomatic (n=10) patients who had a high-grade internal carotid artery stenosis (range, 70% to 99%). Results were compared with those from 10 healthy control subjects.
Results Mean baseline cerebral blood flow was 40.29±138 mL/100 g per minute on the symptomatic side in symptomatic patients versus 45.20±2.53 mL/100 g per minute on the lesion side in asymptomatic patients (control subjects, 46.91±2.11 mL/100 g per minute in the right hemisphere versus 46.17±1.93 mL/100 g per minute in the left). There was no statistical T he importance of hemodynamic factors in the pathogenesis of focal cerebral ischemia remains unclear, whereas embolic risk increases with severe internal carotid artery (ICA) stenosis. 12 The degree of vessel occlusion correlates poorly with the hemodynamic status of the ipsilateral cerebral circulation. 3 Previous studies 4 -5 have demonstrated a poor outcome after ICA occlusion in patients having an insufficient collateral circulation via the circle of Willis. There is also evidence suggesting that areas of brain tissue with marginal perfusion may be more susceptible to the effect of microemboli. 6 Accordingly, thromboembolic transient ischemic attacks (TIAs) or reversible ischemic neurological deficit (RIND) might be expected in patients with a restricted collateral capacity.
The usefulness of an acetazolamide test in assessing the cerebral perfusion reserve 7 has been well estab- difference between patients in symptomatic and asymptomatic groups versus control subjects (P>.10). Mean cerebral blood flow increase after acetazolamide was in the same range in symptomatic (52.89 ±2.54 mL/100 g per minute) and asymptomatic (56.22±3.35 mL/100 g per minute) patients (f>.10), and no difference was observed regarding control subjects (54.25 ±2.94 mL/100 g per minute; P>.10). Three asymptomatic and two symptomatic patients and three control subjects had no significant cerebral blood flow increase after acetazolamide.
Conclusions An additional hemodynamic factor in thromboembolic ischemia related to severe unilateral carotid stenosis might be an unusual finding in patients without apparent hemodynamic induction of symptoms. The lack of significant variation in postacetazolamide cerebral blood flow in some patients and control subjects implies that this procedure may be inconsistent in assessing the cerebral perfusion reserve in the individual case. (Stroke. 1994^5:1010-1013.)
Key Words • acetazolamide • carotid artery diseases • cerebral blood flow sequently greater risk of developing an ischemic stroke. 8 The adverse effects of extracranial arterial occlusive disease on cerebral blood flow (CBF) reserve have previously been somewhat overestimated, as postmortem studies 9 - 10 showed that ICA occlusion frequently remains asymptomatic.
In the present study our aims were to determine first whether symptomatic patients had any significant hemodynamic restriction ipsilateral to carotid occlusive disease compared with patients whose carotid stenosis is asymptomatic and second whether patients with carotid occlusive disease have impaired cerebral perfusion reserve compared with control subjects.
Subjects and Methods
From August 1989 to June 1993, we prospectivery studied 20 patients (17 men and 3 women aged 52 to 78 years; mean, 64±14 years) referred to our stroke unit and in whom documented obstructive disease of the ICA was found. Ten patients were asymptomatic (mean age, 65 ±13 years), and 10 patients (mean age, 63±12 years) experienced either TIAs (n=4) or RIND (n=6). Head computed tomographic (CT) scan was performed in a mean of 2 days (range, 12 hours to 5 days) after the last ischemic event. Patients who had a history of stroke or cerebral CT evidence of recent or old infarct were excluded. The patients had experienced no symptoms from the contralateral cerebral hemisphere or the brain stem. This selection was made to avoid the effects of cerebral infarction on the CBF studies. No patient had orthostatic provoked symptoms that suggested a hemodynamic mechanism. Electrocardiography and transthoracic echocardiography ruled out any cardioem-Scan showing left cerebral blood flow measurements before'and after acetazolamide (ACZ) administration in a 78-year-old woman who experienced transient left arm weakness related to a left internal carotid artery stenosis (80% to 90%). Global left hemispheric value was 40.5 mL/100 g per minute at rest and 60.7 mlV100 g per minute after ACZ test bolic cause of cerebral ischemia. Stenosis was assessed using conventional arteriography and pulsed Doppler ultrasound studies. In asymptomatic patients angiography was done before coronary artery bypass surgery (7 patients) or followed neck ultrasound when a carotid bruit was heard (3 patients). In symptomatic patients angiography was performed between the fourth and sixth day after the last ischemic event. The degree of stenosis was expressed as the maximum percentage reduction in the diameter of the carotid artery according to the criteria of the European Carotid Surgery Trialists.
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CBF estimation was carried out 4 to 10 (median, 7) days after angiography. A double-headed camera (Rota camera, Siemens-France) equipped with two low-resolution (maximum, 15 mm), high-efficiency collimators was used to estimate CBF during a period of 2 minutes after 1.5 minutes of inhalation of 133 Xe. Count rates ranged between 3x10' to 4xlO 6 detected within 4 minutes over each hemisphere. The patients were in the supine position. The inhalation gas mixture contained approximately 50 to 70 mBq/L 133 Xe at the first estimation and ranged between 100 to 120 mBq/L at the second estimation. Each collimator was positioned perpendicular and parallel to the sagittal axis of the brain as close as possible to the subject's skull. Initial slope index (2 minutes) was the parameter examined. Calculation of initial slope index was made using the monocompartmental analysis method described by Fox et al 12 with a correction for Paco?. This method was not tomographic and has been described by Podreka et al. 13 CBF estimation was performed over each hemisphere as shown in the Figure. After an estimation of CBF at baseline, 1 g IV acetazolamide was given, and CBF was estimated 20 minutes later. Cerebral vasoreactivity was calculated as the difference between the two CBF values. The patients were compared with 10 healthy control subjects (8 men and 2 women) comparable in terms of mean age and type of cerebrovascular risk factors. Volunteers had no evidence of carotid artery lesion on neck ultrasound or ischemic lesion on head CT scan. Informed consent was obtained from patients and control subjects.
Statistical Analysis
The results are presented as mean±SEM. The significances of differences between sides, before and after acetazolamide, and groups were assessed with repeated-measures ANOVA with two within factors, side and acetazolamide, and one grouping factor. Computations were performed with the SPSS statistical software package.
Results
In the symptomatic group, 8 patients had a unilateral ICA stenosis ranging between 90% to 99%, and 2 had stenosis ranging between 80% to 90%. In asymptomatic patients, ICA stenosis was estimated between 80% to 90% in 3 patients and between 90% to 99% in 7. Intracranial vessel study did not show any stenosis on carotid siphon or middle cerebral artery. All asymptomatic patients versus 9 in the symptomatic group had collateral flow through the anterior or posterior communicating arteries. Extracranial-intracranial collateral flow through the ophthalmic artery was depicted in 1 symptomatic patient. Tables 1 and 2 summarize clinical, CBF, and angiographic data, respectively, in asymptomatic and symptomatic patients. Table 3 compares CBF   TABLE 1 (mean±SEM) in patients and control subjects before and after the acetazolamide test. Table 4 shows the analysis of differences between patients and control subjects. CBF has been averaged according to both hemispheric values. PCO2 did not vary between patients (4.8 ±0.8%) and control subjects (4.9 ±0.7%) or before and after the acetazolamide test (PCO2 before acetazolamide, 4.8±0.8% mm Hg; PCO2 after acetazolamide, 4.5 ±0.8% mm Hg).
The effects by group and by side between symptomatic and asymptomatic patients were not significant (P>.\0).
The acetazolamide effect was highly significant (P<.001).
Interaction test results were not significant (P>.10). For the control subjects the acetazolamide effect was significant (P<.001), whereas the effect by side was not significant (P>.10).
Between patients and control subjects, group effect was not observed (/ > >.10), whereas acetazolamide effect was highly significant (P<.001); no interaction was found between the acetazolamide and group effect (P>.10). Assessment of the results in individual patients showed that 3 asymptomatic patients (Nos. 1, 5, and 10) and 2 symptomatic (Nos. 1 and 3) had no reactivity versus 3 of the control subjects. No side effects occurred after the administration of acetazolamide.
Discussion
Hemodynamic compromise in occlusive cerebrovascular disease can be estimated by the response to acetazolamide.
8 CBF hyporeactivity to acetazolamide is generally accepted as a method for identifying patients with a restricted collateral capacity in whom carotid endarterectomy could be useful. 1415 A recent study 16 showed that surgery restored baseline CBF values and cerebral vasoreactivity in patients with symptomatic ICA. Nevertheless, patients with convincing signs of carotid distribution "insufficiency" in the hemodynamic sense are rare. 17 '
18 Powers 3 has suggested that patients with impaired perfusion reserve may be more likely to have stagnant flow close to the carotid lesion, which would increase their risk of artery-to-artery thromboembolism. Though the limited number of subjects in each group might prevent the assessment of any difference, no statistically significant difference was found between CBF of symptomatic and asymptomatic patients after the acetazolamide test. Therefore, we can anticipate that an additional hemodynamic factor in thromboembolic ischemia related to severe high-grade ICA stenosis might be lacking. However, cerebrovascular reserve impairment that is often detectable in restricted areas 2 could have been missed, as our estimation of CBF was made over the whole hemisphere.
The lack of hemodynamic factors such as arterial hypotension, positional changes, or exertion might explain these results because an abnormal vasodilatory response is usually expected in patients who have a carotid low-perfusion state favored by these conditions. The vasocapacitance of the cerebral circulation as determined by CBF reactivity to acetazolamide or CO 2 is impaired mainly in those patients who had more severe atheromatous lesions and limited collateral channels. 4 -5 -81419 - 21 Therefore, we suggest that the presence of collateral channels via the circle of Willis in most of our patients might have spared their cerebral vasocapacitance.
The lack of significant variation in CBF response after acetazolamide between patients and control subjects might suggest that the acetazolamide test is an inconsistent procedure to assess the cerebral perfusion reserve in the individual case. Chollet et al 22 found a reactivity to acetazolamide ranging from 8% to 102%. This great variability was not related to ICA lesions as it was also present in patients without ICA lesions.
CBF hyporeactivity to acetazolamide could also be due to a chronic alteration of the microvasculature by hypertension and diabetes mellitus. Either one or both risk factors were present in 5 patients who had no significant CBF increase after acetazolamide. Moreover, acetazolamide failed to show any significant change in 3 control subjects; this last finding reflects clearly a variable sensitivity to acetazolamide. 23 
